ES2167465T3 - Uso de derivados de indol para el tratamiento de trastornos dermatologicos, neuropatias perifericas, artritis, enfermedades alergicas u obstructivas cronicas de las vias respiratorias, glaucoma e inflamacion ocular. - Google Patents

Uso de derivados de indol para el tratamiento de trastornos dermatologicos, neuropatias perifericas, artritis, enfermedades alergicas u obstructivas cronicas de las vias respiratorias, glaucoma e inflamacion ocular.

Info

Publication number
ES2167465T3
ES2167465T3 ES95934662T ES95934662T ES2167465T3 ES 2167465 T3 ES2167465 T3 ES 2167465T3 ES 95934662 T ES95934662 T ES 95934662T ES 95934662 T ES95934662 T ES 95934662T ES 2167465 T3 ES2167465 T3 ES 2167465T3
Authority
ES
Spain
Prior art keywords
glaucoma
arthritis
treatment
peripheral neuropathies
allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95934662T
Other languages
English (en)
Inventor
Paul Gupta
Juan Lahuerta
Shirley Jones
Susan Frances Robson
Gillian Mary Ryder Samuels
Alan Brian Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2167465T3 publication Critical patent/ES2167465T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA INVENCION PROPORCIONA EL USO DE UN COMPUESTO DE LA FORMULA (I) DONDE R{SUP,1} Y R{SUP,2} INDEPENDIENTEMENTE REPRESENTAN H O ALQUIL C{SUB,1}-C{SUB,6}, O UNA SAL ACEPTABLE FARMACEUTICAMENTE DEL MISMO, EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES DERMATOLOGICAS, NEUROPATIAS PERIFERICAS, ARTRITIS, ENFERMEDADES GASTROINTESTINALES O UROGENITALES, DOLOR DE CABEZA ASOCIADO A LA INGESTION DE SUSTANCIAS O RETIRADA DE ESTAS, DOLOR DE CABEZA POR TENSION; MIGRAÑA PEDIATRICA, CEFALEA DISAUTONOMICA POSTRAUMATICA, DOLOR OROFACIAL; ENFERMEDADES OBSTRUCTIVAS DE LAS VIAS AEREAS DE CARACTER ALERGICO O CRONICO; GLAUCOMA O INFLAMACION OCULAR; O PROFILAXIS DE LA MIGRAÑA.
ES95934662T 1994-10-12 1995-10-05 Uso de derivados de indol para el tratamiento de trastornos dermatologicos, neuropatias perifericas, artritis, enfermedades alergicas u obstructivas cronicas de las vias respiratorias, glaucoma e inflamacion ocular. Expired - Lifetime ES2167465T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9420529A GB9420529D0 (en) 1994-10-12 1994-10-12 Indoles

Publications (1)

Publication Number Publication Date
ES2167465T3 true ES2167465T3 (es) 2002-05-16

Family

ID=10762708

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95934662T Expired - Lifetime ES2167465T3 (es) 1994-10-12 1995-10-05 Uso de derivados de indol para el tratamiento de trastornos dermatologicos, neuropatias perifericas, artritis, enfermedades alergicas u obstructivas cronicas de las vias respiratorias, glaucoma e inflamacion ocular.

Country Status (25)

Country Link
US (2) US6455567B1 (es)
EP (1) EP0785781B1 (es)
JP (2) JP3096306B2 (es)
KR (1) KR970705992A (es)
CN (1) CN1160347A (es)
AT (1) ATE210980T1 (es)
AU (1) AU3699795A (es)
BR (1) BR9504375A (es)
CA (1) CA2202484C (es)
CO (1) CO4480025A1 (es)
CZ (1) CZ285633B6 (es)
DE (1) DE69524780T2 (es)
DK (1) DK0785781T3 (es)
ES (1) ES2167465T3 (es)
FI (1) FI971527A (es)
GB (1) GB9420529D0 (es)
HU (1) HUT77317A (es)
IL (1) IL115530A (es)
MX (1) MX9702732A (es)
NO (1) NO971606D0 (es)
PE (1) PE47296A1 (es)
PL (1) PL319868A1 (es)
PT (1) PT785781E (es)
WO (1) WO1996011685A2 (es)
ZA (1) ZA958557B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
DE60135972D1 (de) * 2000-01-18 2008-11-13 Merck & Co Inc Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
MXPA03000729A (es) * 2000-07-28 2004-11-01 Inspire Pharmaceuticals Inc Metodo para reducir la presion intraocular utilizando derivados de indol.
ES2172415B2 (es) 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
EP1452167A1 (de) * 2003-02-28 2004-09-01 Cognis France S.A. Kosmetische, pharmazeutische und/oder dermatologische Zubereitungen enthaltend einen Extrakt aus Eperua falcata
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
DE10337184A1 (de) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US8916611B2 (en) * 2006-04-28 2014-12-23 Warsaw Orthopedic, Inc. Pharmaceutical removal of neuronal extensions from a degenerating disc
US20070253960A1 (en) * 2006-04-28 2007-11-01 Josee Roy Pharmaceutical removal of vascular extensions from a degenerating disc
US9789161B2 (en) 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
CN103479624B (zh) * 2013-10-10 2015-06-17 嵊州市诺米克进出口有限公司 Racemosins A在制备治疗或预防口腔溃疡药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
GB2222768B (en) * 1988-06-17 1992-01-22 Nat Res Dev Analgesic compounds and compositions
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
DE9190141U1 (es) * 1990-10-15 1993-07-15 Pfizer, Inc., New York, N.Y., Us
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
DE69230803T2 (de) 1991-11-25 2000-12-07 Pfizer 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
US5409941A (en) 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (es) 1992-03-05 1996-10-11 Pfizer
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
JP2644088B2 (ja) 1992-04-07 1997-08-25 フアイザー・インコーポレイテツド ５−ｈｔ１作動薬としてのインドール誘導体
BR9306221A (pt) 1992-04-10 1998-06-30 Pfizer Derivados do acilaminoindol como agonistas 5-htl
GB9207930D0 (en) 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) 1992-04-14 1992-05-27 Pfizer Ltd Indoles
TW251284B (es) 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
PL311204A1 (en) 1993-04-22 1996-02-05 Pfizer Res & Dev Indole derivatives as antagonists of 5-ht-like receptors for use in hemicrania
GB9317096D0 (en) 1993-08-17 1993-09-29 Pfizer Ltd Indoles
AU686654B2 (en) 1993-08-31 1998-02-12 Pfizer Inc. 5-arylindole derivatives
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420503D0 (en) 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9424471D0 (en) 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis

Also Published As

Publication number Publication date
WO1996011685A3 (en) 1996-08-15
GB9420529D0 (en) 1994-11-30
IL115530A0 (en) 1996-05-14
FI971527A0 (fi) 1997-04-11
PE47296A1 (es) 1996-11-12
AU3699795A (en) 1996-05-06
NO971606L (no) 1997-04-08
JP3096306B2 (ja) 2000-10-10
PT785781E (pt) 2002-04-29
DK0785781T3 (da) 2002-03-18
KR970705992A (ko) 1997-11-03
CA2202484C (en) 2001-12-18
EP0785781B1 (en) 2001-12-19
PL319868A1 (en) 1997-09-01
ZA958557B (en) 1997-04-11
FI971527A (fi) 1997-04-11
JPH09511755A (ja) 1997-11-25
CA2202484A1 (en) 1996-04-25
US6455567B1 (en) 2002-09-24
US20030055098A1 (en) 2003-03-20
WO1996011685A2 (en) 1996-04-25
ATE210980T1 (de) 2002-01-15
NO971606D0 (no) 1997-04-08
HUT77317A (hu) 1998-03-30
EP0785781A2 (en) 1997-07-30
DE69524780T2 (de) 2002-06-13
CO4480025A1 (es) 1997-07-09
CN1160347A (zh) 1997-09-24
BR9504375A (pt) 1997-04-08
DE69524780D1 (de) 2002-01-31
JP2000080036A (ja) 2000-03-21
IL115530A (en) 2001-03-19
CZ111897A3 (cs) 1998-06-17
MX9702732A (es) 1997-06-28
CZ285633B6 (cs) 1999-10-13

Similar Documents

Publication Publication Date Title
ES2167465T3 (es) Uso de derivados de indol para el tratamiento de trastornos dermatologicos, neuropatias perifericas, artritis, enfermedades alergicas u obstructivas cronicas de las vias respiratorias, glaucoma e inflamacion ocular.
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
RU94042466A (ru) Фармацевтически активные бициклические гетероциклические амины
NO20045656L (no) Oftalmologisk anvendelse av roflumilast for behandlingen av oyesykdommer
ITMI911299A1 (it) Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
RU95114405A (ru) Применение рилузола в качестве лекарственного средства для лечения неврологических нарушений, вызванных травмами и способ получения лекарственного средства
CY1109869T1 (el) Παραγωγη πεπτιδιων και φαρμακευτικα αποδεκτων αλατων τους, τροποι συνθεσης, χρησης και φαρμακευτικης συνθεσης
WO2002009702A8 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
ES2134709B1 (es) Utilizacion de los derivados de 1-(4-(4-aril (0 heteroaril)-1-piperazinil)-butil)-1h-azol para la preparacion de un medicamento destinado al tratamiento de los transtornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis y del mareo en los m
FI92320C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
CA2185883C (en) The use of dimeticone as a transport and carrier system and/or drug delivery system
IT1276462B1 (it) Diamidi aromatiche acide ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico
CO5011065A1 (es) Ligandos del receptor h3, del tipo fenil-alquil-imidazoles
PT1082116E (pt) Utilizacao de derivados de 4-piperidinometanol no tratamento de desordens do neurodesenvolvimento
ECSP951549A (es) Nuevo procedimiento de tratamiento
KR950701518A (ko) 알쯔하이머 질환의 치료에 있어서 (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민의 용도(Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatmet of Alzheimer's disease)
RU97108290A (ru) Использование производных индола для лечения различных заболеваний, новый способ лечения
NZ282805A (en) Use of dimethylpolysiloxane (dimeticone) as a carrier in medicaments